Gus3 neuropeptides for regulating hypothalamic function
OwnerLeif Kongskov Larsen, Sarag Paulseninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to use of GUS3 neuropeptides or functional variants in a medicament. The invention furthermore relates to specific medical uses of such neuropeptides, for regulating hypothalamic function.
Claims25
Use in a medicament of at least one compound selected from:
- a peptide with the sequence defined in SEQ ID NO 2;
- a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2;
- a functional variant of any of these peptides;
- a modulator of any of these peptides;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- a DNA sequence encoding any of these peptides;
- and an antisense-polynucleotide to a nucleotide sequence encoding any of these peptides.
Use in a medicament of antibodies that are specific to at least one compound selected from:
- a peptide with the sequence defined in SEQ ID NO 2;
- a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2;
- a functional variant of any of these peptides;
- and a modulator of any of these peptides.
A method of preventing, treating or regulating a hypothalamic function and/or disorder in an animal, comprising administering to the animal an effective amount of at least one active compound selected from:
- SEQ ID NO 2;
- residues 66-125 from SEQ ID NO 2;
- residues 53-63 from SEQ ID NO 2;
- residues 26-50 from SEQ ID NO 2;
- a functional variant of any of these peptides;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- antibodies specific to at least one of these peptides, a DNA sequence encoding any of these peptides;
- and an anti-sense nucleotide to a nucleotide sequence encoding any of these peptides.
A pharmaceutical composition for regulating a hypothalamic function comprising a siRNA polynucleotide specific for one of the following:
- a polynucleotide encoding peptide with the sequence defined in SEQ ID NO 2;
- a polynucleotide encoding a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a polynucleotide encoding a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a polynucleotide encoding a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- a DNA sequence encoding any of these peptides;
- and a polynucleotide encoding a functional variant of any of these peptides.
A method of identifying an interaction partner to GUS3 comprising using at least one compound selected from:
- a peptide with the sequence defined in SEQ ID NO 2;
- a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- a functional variant of any of these peptides;
- and a DNA sequence encoding any of these peptides;
- to screen an expression library for interaction partners.
A method of identifying a modulator of GUS3 comprising using a compound selected from:
- a peptide with the sequence defined in SEQ ID NO 2;
- a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2, a functional variant of any of these peptides, and a peptide that binds polyclonal antibodies raised against any of these peptides;
- to screen an array of compounds for binding partners and subsequently determining the effect of this binding upon the biological activity of GUS3.
A method of diagnosing or prognosticating a metabolic disorder in an animal comprising determining the sequence of the polynucleotide, which encodes GUS3, and comparing the sequence with SEQ ID NO:
- 1 to identify differences in the sequence and using this information for diagnostic and/or prognostic purposes.
A method of effecting a change in water and/or food intake in an animal comprising administering to the animal an effective amount of a compound selected from:
- a peptide with the sequence defined in SEQ ID NO 2;
- a peptide with the sequence defined by residues 66-125 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 53-63 from SEQ ID NO 2;
- a peptide with the sequence defined by residues 26-50 from SEQ ID NO 2;
- a functional variant of any of these peptides;
- a peptide that binds polyclonal antibodies raised against any of these peptides;
- and a DNA sequence encoding any of these peptides.
Dependencies are inferred from the claim text.